Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Citation

As Published
http://dx.doi.org/10.1073/pnas.1019559108

Publisher
National Academy of Sciences

Version
Final published version

Accessed
Tue Apr 04 02:06:51 EDT 2017

Citable Link
http://hdl.handle.net/1721.1/67357

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.

Detailed Terms

Please share how this access benefits you. Your story matters.
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Ryohei Katayama\textsuperscript{a,b}, Tahsin M. Khan\textsuperscript{a,c}, Cyril Benes\textsuperscript{a,b}, Eugene Lifshits\textsuperscript{a}, Hiromichi Ebi\textsuperscript{a,b}, Victor M. Rivera\textsuperscript{d}, William C. Shakespeare\textsuperscript{e}, A. John Iafrate\textsuperscript{b,e}, Jeffrey A. Engelman\textsuperscript{a,b,1} and Alice T. Shaw\textsuperscript{a,b,c,1}

\textsuperscript{a}Massachusetts General Hospital Cancer Center, Boston, MA 02129; \textsuperscript{b}Department of Medicine, Harvard Medical School, Boston, MA 02115; \textsuperscript{c}Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; \textsuperscript{d}ARIAD Pharmaceuticals, Cambridge, MA 02139; and \textsuperscript{e}Department of Pathology, Massachusetts General Hospital, Boston, MA 02114

Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved March 23, 2011 (received for review December 27, 2010)

The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a molecular target in a small subset of non-small cell lung cancers (NSCLCs). This fusion leads to constitutive ALK activation with potent transforming activity. In a pivotal phase 1 clinical trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions. However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clinical benefit. To determine how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-positive NSCLC cell line to increasing doses of crizotinib until resistance emerged. We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene. Cells resistant to higher doses (1 \textmu M) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib. This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay. Although crizotinib was ineffective against EML4-ALK harboring the gatekeeper mutation, we observed that two structurally different ALK inhibitors, NVP-TAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo. Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG. Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.

First described in 2007, the oncogenic fusion kinase echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) is present in \textasciitilde4% of patients with non-small cell lung cancer (NSCLC) (1). Chromosomal translocations involving ALK also occur in other cancers, including anaplastic large cell lymphomas and inflammatory myofibroblastic tumors. In all cases, the fusion partner (e.g., EML4) is believed to mediate ligand-independent oligomerization of ALK, resulting in constitutive ALK kinase activation (2–4). In cell line and genetically engineered mouse models, EML4-ALK serves as a potent oncopogenic “driver,” and cancers with this translocation are highly sensitive to ALK kinase inhibition (5, 6). Recently, a tyrosine kinase inhibitor (TKI) targeting ALK, crizotinib (PF-02341066), was examined in a phase 1 trial (7). Among 105 patients with EML4-ALK-positive NSCLC, crizotinib showed remarkable activity, with an objective response rate of 56% and a median progression-free survival of 9.2 mo (7, 8). These results support the notion that lung cancers harboring EML4-ALK are highly susceptible to ALK-targeted therapies and demonstrate the properties of “oncogene addiction” to ALK.

Although many patients derive substantial clinical benefit, the development of drug resistance has curbed the impact of crizotinib in this disease. The paradigm of acquired TKI resistance has been seen with other targeted therapy successes, including epidermal growth factor receptor (EGFR) mutant lung cancers and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutant melanomas (9–16). Similar to the experience with crizotinib, sensitive cancers ultimately develop resistance, usually within 1 y. For example, most patients with EGFR-mutant NSCLC will have disease progression after 9–12 mo of EGFR TKI monotherapy. In about one-half of cases, resistance arises due to the acquisition of a secondary gatekeeper mutation (T790M) within the EGFR (13, 15, 16). This mutation leads to substitution of a threonine in the ATP-binding pocket with a bulky methionine residue, which hinders drug binding. In about 10–20% of cases, resistance arises as a result of focal amplification of the MET proto-oncogene (9, 16, 17). Importantly, preclinical modeling of acquired resistance to EGFR TKIs has proven invaluable, not only for accurately predicting the resistance mechanisms that emerge in the clinic, but also for assessing new therapeutic strategies to overcome resistance (12, 16–22).

Recently, one NSCLC patient with acquired resistance to crizotinib was described (23). In this patient who relapsed after 5 mo of treatment, molecular analyses revealed that the resistant tumor cells harbored two secondary mutations within the kinase domain of EML4-ALK, C1156Y, and the gatekeeper mutation L1196M. These mutations occurred independently in distinct subclones of the resistant tumor. Studies of Ba/F3 cells engineered to express EML4-ALK harboring either mutation suggested that these mutants were resistant to crizotinib as well as resistant to a more potent ALK TKI, termed 2,4-pyrimidinediamine derivative (PDD). Thus, strategies to overcome this type of resistance have not yet been established. In addition, because there are no laboratory models of acquired resistance via this mechanism, it remains unknown if cancers that develop these resistance mutations remain addicted to ALK kinase activity and will be highly sensitive to other therapeutics targeting ALK.

In this study, we have explored resistance to crizotinib by generating and characterizing a unique cell line model of acquired resistance. In this model of acquired resistance, EML4-ALK is amplified and harbors the L1196M gatekeeper mutation. We show that cells expressing the L1196M mutant form of EML4-ALK are resistant to crizotinib, remain addicted to ALK signaling, and are highly sensitive to other ALK inhibitors.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

To whom correspondence may be addressed. E-mail: jengelman@partners.org or ashaw1@partners.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1019559108/-/DCSupplemental.
and are highly sensitive to other structurally distinct ALK TKIs as well as to Hsp90 inhibition. On the basis of these results, we propose two therapeutic strategies for overcoming acquired resistance to crizotinib, particularly when mediated by secondary mutations within the ALK TK domain.

Results

Generation and Biochemical Characterization of Crizotinib-Resistant Cells. The NSCLC cell line H3122 expresses EML4-ALK variant 1 and is highly sensitive to treatment with crizotinib. To explore mechanisms of crizotinib resistance, we generated resistant H3122 clones by exposing the sensitive parental cells to increasing concentrations of crizotinib for 4 mo. We maintained cells with intermediate crizotinib resistance, referred to as H3122 CR0.6, in 600 nM of crizotinib. The fully resistant cells, H3122 crizotinib-resistant (H3122 CR) cells, were maintained in 1 μM of crizotinib.

H3122 CR cells were as resistant to crizotinib as other cancer cell lines that did not harbor ALK gene rearrangements (IC50 > 1 μM; Fig. L4 and SI Appendix, Fig. S1A). In addition, we assessed 704 established cancer cell lines derived from a wide variety of tumor types for sensitivity to crizotinib as part of our automated platform to examine drug sensitivity across multiple cell lines (24). Whereas parental H3122 cell lines segregated with the most sensitive cell lines, the H3122 CR cells segregated with the highly resistant cell lines (Fig. 1B). Unlike the parental H3122 cells, the H3122 CR cells maintained ALK phosphorylation in the presence of crizotinib (Fig. 1C). Accordingly, AKT and ERK phosphorylation were not suppressed by crizotinib in the resistant cells. Notably, H3122 CR cells also contained higher total protein levels of EML4-ALK compared with the parental line (Fig. 1C).

EML4-ALK Gene Is Amplified and Mutated in H3122 CR Cells. To determine whether gene amplification underlies the elevated protein level of EML4-ALK in H3122 CR cells, we performed fluorescence in situ hybridization (FISH) analysis. Relative to parental H3122 cells, H3122 CR cells showed an increase in the number of rearranged EML4-ALK genes per cell (Fig. 2A).

Because the phosphorylation of EML4-ALK in H3122 CR cells is not impacted by 1 μM crizotinib (Fig. 1C), we hypothesized that resistant cells might also harbor a mutation within ALK. We prepared cDNA and examined the entire coding sequence of EML4-ALK in H3122 parental and resistant cells. In the resistant cells, we detected a C → A substitution at nucleotide 3586 of EML4-ALK variant 1 (Fig. 2B) that was not detected in the parental cells. This 3586C → A substitution results in a leucine → methionine change within the ALK TK domain, corresponding to the L1196M gatekeeper mutation previously reported in a patient with acquired resistance to crizotinib (23). We did not detect any other TK mutations including the C1156Y substitution, which was also reported in the same patient (23). Consistent with the notion that this L1196M mutation confers resistance to crizotinib, Ba/F3 cells engineered to express this mutant were also resistant to crizotinib, whereas cells expressing wild-type EML4-ALK were sensitive (SI Appendix, Fig. S2). Notably, in the DNA sequence tracings, the peak corresponding to the mutation is approximately one-half to one-third as high as the wild-type peak (Fig. 2B). This suggests that only a fraction of the amplified EML4-ALK fusion genes acquire the secondary resistance mutation.

These resistant models were developed by stepwise increases in drug concentration until fully resistant cells emerged. Because both amplification and mutation were identified in H3122 CR cells, we sought to investigate the temporal relationship between gene amplification and secondary mutation in acquired crizotinib resistance. Thus, we analyzed H3122 CR0.6 cells, the intermediate, partially resistant predecessors of H3122 CR cells that were resistant to 600 nM crizotinib. By Western blotting analysis, ALK protein level and p-ALK were up-regulated in H3122 CR0.6 cells (SI Appendix, Fig. S3). FISH analysis demonstrated amplification of the EML4-ALK fusion gene in the H3122 CR0.6 cells (Fig. 2C). However, they did not harbor a secondary ALK resistance mutation (Fig. 2B). To determine whether L1196M is present at a low level in a subpopulation of H3122 CR0.6 cells, we developed a highly sensitive gatekeeper mutation-specific PCR assay that can detect the L1196M mutation when it represents at least 1% of the mutated ALK alleles (SI Appendix, Fig. S4). Using this assay, we detected L1196M in H3122 CR0.6 cells and in all 11 clones derived from single H3122 CR0.6 cells (SI Appendix, Fig. S5), but not in the H3122 CR0.6 cells, the parental H3122 cells, or the other NSCLC cell lines harboring EML4-ALK (Fig. 2C and SI Appendix, Fig. S5). These results suggest that the L1196M mutation is present in each cell of the resistant H3122 CR cells and that there is a stepwise model of acquired resistance involving amplification of the target, which confers resistance to 600 nM crizotinib, followed by sec-

![Fig. 1](https://www.pnas.org/cgi/doi/10.1073/pnas.1019559108)
ondary gatekeeper mutation that renders cells resistant to 1 μM crizotinib.

**H3122 CR Cells Are Addicted to ALK.** To determine if H3122 CR cells continue to require EML4-ALK for their viability, we used siRNAs targeting ALK to knock down EML4-ALK. In both H3122 parental and H3122 CR cell lines, ALK-specific siRNA decreased expression of EML4-ALK and potently suppressed cell growth (Fig. 3A and B). As expected, the ALK siRNA had no effect on the growth of KRAS mutant A549 cells (Fig. 3A and B). These results demonstrate that resistant H3122 CR cells expressing EML4-ALK L1196M remain addicted to ALK signaling.

**NVP-TAE684 and AP26113 Overcome Crizotinib Resistance in H3122 CR Cells.** Based on the crystal structure of the kinase domain of ALK, the gatekeeper L1196M mutation causes resistance by steric interference with crizotinib binding (23). Thus, although resistant to crizotinib, this mutant ALK may be sensitive to structurally distinct ALK kinase inhibitors. To address this hypothesis, we tested the activity of the ALK inhibitor NVP-TAE684, a 5-chloro-2,4-diaminophenylpyrimidine, in parental and resistant H3122 cells. As shown in Fig. 4, NVP-TAE684 markedly reduced cell survival in both sensitive H3122 and H3122 CR cells, but had little to no effect on the viability of other, non-ALK–dependent cancer cell lines (Fig. 4A and SI Appendix, Fig. S1B). Within the panel of 704 established cancer cell lines assessed in the automated platform (24), the vast majority were largely insensitive to 200 nM NVP-TAE684; however, 1% of lines displayed marked sensitivity to NVP-TAE684. Both the H3122 and the H3122 CR cell lines segregate with the highly sensitive cell lines (Fig. 4B). This is in sharp contrast to the resistance of H3122 CR cells to crizotinib (Fig. 1B). In contrast to crizotinib, NVP-TAE684 treatment of H3122 CR cells suppressed phosphorylation of ALK, AKT, and ERK and induced marked apoptosis (Fig. 4C and SI Appendix, Fig. S6). Similarly, NVP-TAE684 potently suppressed the survival of Ba/F3 cells expressing the EML4-ALK L1196M mutant (SI Appendix, Fig. S7A). However, in this system, the potency of NVP-TAE684 against mutant EML4-ALK was slightly reduced relative to native EML4-ALK, with IC50 values of 2.7 versus 1.2 nM, respectively.
We also tested a second, structurally distinct ALK kinase inhibitor, AP26113. A new highly selective small molecule inhibitor of ALK, AP26113 exhibits about fivefold greater potency in vitro compared with crizotinib (SI Appendix, Table S1A). Like NVP-TAE684, AP26113 was highly active against both sensitive and resistant H3122 cells, decreasing cell growth (Fig. 4D and SI Appendix, Fig. S1C), suppressing ALK phosphorylation (Fig. 4E), and inducing apoptosis (SI Appendix, Fig. S6). Higher doses of AP26113 were required to completely suppress ALK in the resistant cells because there were greater levels of ALK/p-ALK as a result of gene amplification. AP26113 was also active in Ba/F3 cells expressing either native or mutant EML4-ALK (IC_{50}’s were 10 and 24 nM, respectively) (SI Appendix, Fig. S7B). Consistent with the Ba/F3 data, the potency of AP26113 against mutant EML4-ALK was slightly reduced relative to native EML4-ALK as determined by its capacity to decrease p-ALK in the H3122 and H3122 CR cells, with IC_{50} values of 7.4 versus 16.8 nM, respectively (SI Appendix, Fig. S8). These results suggest that AP26113 can overcome crizotinib resistance mediated by the gatekeeper L1196M mutation. Indeed, we observed impressive in vivo activity of both NVP-TAE684 and AP26113, but not of crizotinib, against the H3122 CR cells grown as xenograft tumors in vivo (SI Appendix, Fig. S9).

**Hsp90 Inhibitor 17-AAG Overcomes Crizotinib Resistance in H3122 CR Cells.** In a recent phase 2 study, the Hsp90 inhibitor IPI-504 demonstrated clinical activity in three of three patients with ALK-positive NSCLC and induced rapid degradation of EML4-ALK in vitro (25). Hsp90 inhibitors also induced tumor regression in a genetically engineered mouse model of lung cancer driven by EML4-ALK (5). Therefore, we evaluated the efficacy of the Hsp90 inhibitor 17-AAG in EML4-ALK L1196M-expressing cells. As shown in Fig. 5A, 17-AAG potently suppressed cell growth in both parental H3122 and H3122 CR cells, but not in other non-ALK-dependent lung cancer lines (SI Appendix, Fig. S1D). However, in contrast to NVP-TAE684 and AP26113, 17-AAG also inhibited the viability of SKBR3 and BT474 cell lines, both of which harbor HER2 amplification and are known to be sensitive to Hsp90 inhibition (26, 27). In Ba/F3 cells, 17-AAG was active against both...
Dasatinib and nilotinib is under clinical development for ALK.

EML4-ALK is a known oncogenic event and the same L1196M gatekeeper mutation that was found in pediatric neuroblastoma (34), amplification of EML4-ALK fusion oncogenes has not been reported. Analysis of partially resistant H3122 cells (H3122 CR0.6) that harbor EML4-ALK amplification (but no gatekeeper mutation) suggests a step-wise evolution of acquired resistance involving gene amplification followed by point mutation. This model is also supported by the observation that only a fraction of the amplified ALK fusion genes (per cell) harbor L1196M (Fig. 2C). In other TKI-resistant cancers, target amplification preceding acquisition of secondary mutations has not been reported in vitro or in vivo. It remains unknown if this two-step mechanism is unique to EML4-ALK–positive NSCLC or if it is a product of the methodology used to develop resistance in the laboratory.

The detection of gatekeeper and other acquired mutations in resistant tumor samples is clinically important, but can be technically challenging. The EGFR T790M resistance mutation, for example, is often difficult to detect on standard sequence tracings and may require more sensitive techniques such as deep sequencing for detection (19, 35, 36). This problem may be due to contamination of the tumor specimen with noncancerous cells (e.g., stromal or inflammatory, cells). Alternatively, for some tumors, only a small percentage of the EGFR alleles per cell may harbor the T790M mutation (termed “allelic dilution”), or only a small percentage of resistant cells in the tumor specimen might have T790M-mediated resistance. Notably, the finding of both EML4-ALK amplification and L1196M mutation in the CR cells suggests that allelic dilution also could ultimately contribute to difficulty in detecting resistance mutations in cancers with acquired resistance to crizotinib. In this study, we developed an L1196M-mutation specific PCR assay to detect potentially low levels of the gatekeeper L1196M mutation in partially resistant H3122 CR0.6 cells. This assay is highly sensitive with a detection limit of 1% or less (SI Appendix, Fig. S4) and requires only 30 ng genomic DNA. Thus, this assay might serve as the basis for a clinical diagnostic test for L1196M in biopsy samples from crizotinib-resistant patients.

In both CML and EGFR-mutant lung cancer, resistant tumors with gatekeeper mutations have proven refractory to second-generation, more potent TKIs. One recent report suggests that the gatekeeper mutation in ALK might behave similarly; compared with control Ba/F3 cells expressing native EML4-ALK, cells expressing mutant EML4-ALK L1196M were markedly less sensitive to a potent PDD (23). In contrast, we have found that crizotinib resistance mediated by the gatekeeper L1196M mutation can be effectively overcome by two different ALK TKIs. Importantly, one of these—AP26113—is under clinical development and is scheduled to begin clinical testing within the year. In H3122 CR cells, the improved cellular activity of AP26113 compared with crizotinib is likely based on both its enhanced potency against ALK and its increased activity against L1196M-mutated ALK. In vitro kinase assays revealed that wild-type and L1196M-mutated ALK showed similar $K_{i}$ values for ATP binding (30.7 and 27.2 μM, respectively). However, crizotinib was about 10-fold less potent against L1196M ALK compared with wild-type ALK ($K_{i}$ of 8.2 and 0.7 nM, respectively), consistent with its diminished efficacy against the L1196M ALK in cell lines (SI Appendix, Table S1B). In contrast, AP26113 was ~10-fold more potent against ALK than crizotinib in vitro, and unlike crizotinib, it was similarly potent against the L1196M mutant ($K_{i}$ of 0.09 and 0.08 nM, respectively).

In addition to studying ALK TKIs, we have shown that EML4-ALK harboring the gatekeeper mutation is an Hsp90 client protein similar to wild-type EML4-ALK and sensitive to Hsp90 inhibition. Notably, cell lines expressing either native EML4-
ALK or EML4-ALK L1196M were even more sensitive to 17-AAG than two Hsp90-dependent, HER2-amplified breast cancer lines (Fig. 5A). Therefore, patients with crizotinib resistance due to an acquired L1196M mutation may derive benefit from two different ALK-targeted strategies: more potent ALK TKIs such as AP26113 or any of a number of Hsp90 inhibitors already in clinical trials. Notably, although gatekeeper mutations are particularly common in EGFR-mutant lung cancer, the frequency of L1196M in EML4-ALK-positive NSCLC has yet to be established. Because secondary mutations such as the gatekeeper mutation may not represent the predominant mechanism of acquired crizotinib resistance, additional studies are needed to elucidate other mechanisms of resistance. The results of these studies will be critical to selecting the best therapeutic strategies for targeting TKI resistance in the clinic.

Materials and Methods
See SI Appendix for the description of the cell culture conditions, generation of H3122 CR cells, survival assays, fluorescence in situ hybridization, immunoblotting, apoptosis assay retroviral infection, quantitative RT-PCR (qPCR), siRNA transfection, xenograft study, and statistical analyses.

Reagents. Crizotinib and NVP-TAE684 were purchased from ChemieTek and 17-AAG was purchased from Selleck. AP26113 was provided by ARIAD Pharmaceuticals that makes AP26113 available to qualified academic laboratories free of charge for verification and reproduction of the results reported in this paper. Each compound was dissolved in DMSO for cell culture experiments. Control or ALK siRNA was from Invitrogen, and HiPerfect reagent was from Qiagen.

Isolation of Genomic DNA Preparation and L1196M Mutation-Specific PCR. Genomic DNA was isolated from cell pellets with a DNeasy kit (Qiagen) according to the manufacturer’s protocol. Exon 23 of ALK was PCR-amplified from genomic DNA using Pfu Ultra II (Agilent Technologies) and sequenced bidirectionally with Sanger dideoxynucleotide sequencing with the primers described in SI Appendix. ALK-Exon23 or L1196M mutation-specific qPCR was performed by a LightCycler 480 (Roche Diagnostics) with CYBR Green Master Mix (Roche). Primer sequences are provided in SI Appendix.

ACKNOWLEDGMENTS. This study was supported in part by a V Foundation for Cancer Research Translational Grant (to J.A.E. and A.T.S.), by the Charles W. and Jennifer C. Johnson Koch Institute Clinical Investigator Award (to A.T.S.), by National Institutes of Health K08 Grant CA120060-01 (to J.A.E.), by the Brigham Lung Cancer Research Fund, by the Massachusetts General Hospital Thoracic Oncology Fund, and by a Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to R.K.).